US Capacity Growth MSN Pharmaceuticals Inc. operates a state-of-the-art finished-dosage manufacturing facility in Piscataway, NJ and has expanded into Green, Ohio, signaling a scalable US footprint. This positions MSNPI as a reliable, domestically sourced CDMO for US‑based pharma and biotech companies seeking secure supply chains, high-volume production, and fast market access for finished dosage forms.

Custom & Diverse Formulations With capabilities to deliver high-quality formulations across diverse dosage forms and to offer custom manufacturing, MSNPI can attract clients launching new products or needing tailored dosage forms, enabling rapid onboarding, formulation flexibility, and scalable production.

IP Risk & Mitigation Recent patent litigation involving Entresto underscores IP risk in the generic space. Position MSNPI as a partner for responsible development through robust IP screening, freedom-to-operate assessments, and non-infringing process development to shorten time-to-market for clients.

R&D Alliances MSNPI benefits from an innovation-focused ecosystem and group-level collaborations with MSN Laboratories and Bits Pilani, enabling joint development programs, accelerated formulation optimization, and technology transfer support for US customers seeking new or improved products.

Growth & Partnerships The company’s expansions and mid-market revenue profile indicate opportunities for long-term CDMO partnerships, multi-site production, and risk-sharing contracts; target mid-sized pharma/biotech firms in the US seeking scalable production, process development, tech transfer, and scale-up capabilities.